WGS: GeneDx Holdings Market Cap to Revenue Ratio

Symbol and logo of brand Sema4 (WGS)

GeneDx Holdings Corp. (WGS) is shielded from international sanctions due to its localization in the US. The company leads in the diagnosis of rare pathologies by sequencing exomes for clinics and families. Process automation and AI optimize genome analysis. The P/S ratio trend demonstrates the market valuation of revenue, where the indicator reaches 3.40, reflecting a balance between technological development and investment demand.

GeneDx Holdings (WGS): Price-to-Revenue Ratio from 04/28/2023 to 11/16/2026

Metric breakdowns and analytics for genedx.com (WGS)

- current price and projected stock value:
- market capitalization information:
Summary company analytics:GeneDx, WGS
Manufactured product of GeneDx Holdings Corp.

The P/S multiple determines the market value of one unit of annual revenue, allowing an investor to assess the degree to which an asset is overbought relative to its actual cash flows. When analyzing the calculated price-to-sales ratio, it should be noted that the high valuation of GeneDx Holdings Corp. (WGS) is justified by its ownership of a unique DNA database and strict CLIA standards, which create significant barriers to entry for competitors.

Competing companies

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Price-to-Sales Ratio RARE (Ultragenyx)|Market Cap to Revenue BEAM|P/S Multiple Sarepta Corp|Price-to-Revenue Ratio Twist Bioscience, Inc. (TWST)|Market Cap to Revenue 10x Genomics TXG|Price-to-Revenue Ratio Intellia Therapeutics NTLA|Market Cap to Sales Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Price-to-Revenue Ratio|Price to Sales Wave Pharma|mazetx.com (MAZE) - Price-to-Revenue Ratio|SION - Price-to-Revenue Coefficient|PRME (Prime Medicine Inc) - P/S Multiple|Taysha Gene Therapies, Inc. - Price-to-Sales Ratio|P/S Multiple QURE|MGTX: Price-to-Sales Ratio|Price-to-Revenue Ratio REGENXBIO RGNX|SLDB: Market Cap to Revenue Ratio|OCGN: Market Cap to Revenue|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio